In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.
The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.
An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.
The PCSK9 inhibitor evolocumab appears to be safe and effective for reducing LDL cholesterol in older patients.
Review shows no changes for rheumatoid arthritis patients with tumor necrosis factor antagonist treatment.
Two studies show that PCSK9 inhibition lowered LDL cholesterol in heterozygous and homozygous familial hypercholesterolemia.
Long-term statin use among children with familial hypercholesterolemia is associated with normalization of carotid intima-media thickness progression.
Sanofi and Regeneron announced positive results from four phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia.
Amgen announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for evolocumab for the treatment of high cholesterol.
Cutting traditional risk factors could eliminate significant amount of cardiovascular disease
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Cochrane Data Release and the Case for "Open Science"
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities
- Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D
- Shift Seen From EDs to Urgent Care for Low-Acuity, Acute Care